-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] According to statistics, 449 pharmaceutical companies in A-shares have disclosed their performance in the first half of 2022, and more than 40% of the companies have achieved both revenue and net profit growth
.
It is worth mentioning that 14 pharmaceutical companies including Jiu’an Medical, Mindray Medical, and WuXi AppTec achieved a net profit of more than 2 billion yuan
.
According to the semi-annual performance report released by Jiu'an Medical, in the first half of this year, the company achieved a net profit attributable to the parent of 15.
244 billion yuan, a year-on-year increase of 27728.
49%; the deducted non-net profit was 15.
286 billion yuan, a year-on-year increase of 319,397.
92%
.
Jiu'an Medical said that the company's performance growth was mainly driven by the substantial increase in the sales of iHealth series products, but the demand for products is directly related to the development of the epidemic in the United States and local epidemic prevention policies
.
The uncertainty of the epidemic is strong, so the demand, sales and company performance of the company's products are not particularly stable
.
In the first half of this year, Mindray Medical achieved a net profit of 5.
288 billion yuan attributable to its parent, a year-on-year increase of 21.
71%; and a non-net profit of 5.
247 billion yuan, a year-on-year increase of 21.
76%
.
Regarding the substantial growth in performance, Mindray Medical stated that first, the company's main business continued to show a good development trend during the reporting period, and the product competitiveness continued to strengthen, and the mid-to-high-end sales of the product structure increased steadily; second, the company focused on the direction of strategic development planning, steadily Promoting various tasks in an orderly manner, actively exerting operational advantages in R&D, technology, procurement, manufacturing, quality, products, markets, channels, services, etc.
, integrating business resources, and continuously increasing market development efforts, both product sales and income have been achieved.
Healthy and stable growth; at the same time, the company's management has strengthened the continuous improvement of operating efficiency, so the growth of net profit is higher than that of operating income, and the net profit margin has improved significantly
.
In the first half of the year, WuXi AppTec realized a net profit of 4.
636 billion yuan attributable to shareholders of listed companies, a year-on-year increase of 73.
29%; deducted non-net profit of 3.
850 billion yuan, an increase of 81% year-on-year
.
WuXi AppTec attributed its performance growth in the first half of this year to the company's continued strengthening of its unique integrated CRDMO (Contract Research, Development, and Manufacturing) and CTDMO (Contract Testing, R&D, and Manufacturing) business models, while actively cooperating with the implementation of epidemic prevention in Shanghai.
Control measures to give full play to the advantages of global layout, multi-location operation and coverage of the whole industry chain
.
Zhifei Biological realized a net profit of 3.
729 billion yuan attributable to owners of the parent company
.
It is reported that in the first half of the year, Zhifei Biotechnology continued to focus on the vaccine industry, optimize resource allocation, fully ensure the research and development progress, production and supply of each product under development, continue to increase research and development investment, innovate research and development technology, and continue to make efforts closely around the annual business development goals.
, implement the "technology + market" two-wheel-driven development model, and achieve continuous growth in sales revenue
.
Daan Gene achieved a net profit of 3.
595 billion yuan in the first half of the year, a year-on-year increase of 124.
96%
.
The company stated that the substantial growth in sales of nucleic acid detection kits is the main driving force behind the substantial growth in revenue and net profit in the first half of 2022
.
In the first half of the year, Anxu Bio achieved a net profit of 2.
878 billion yuan attributable to its parent, a year-on-year increase of 1323.
7%
.
Regarding the sharp increase in net profit, the company stated that it was mainly due to the substantial increase in the company's operating income and the simultaneous increase in net profit during the reporting period
.
It is reported that in the first half of the year, the company achieved revenue of 5.
93 billion yuan, a year-on-year increase of 1100.
35%
.
In the first half of the year, Mingde Bio achieved a net profit of 2.
76 billion yuan, a year-on-year increase of 376.
29%
.
It is reported that in the first half of the year, the company's immunodiagnostic product revenue increased significantly year-on-year
.
The company's antigen detection reagents recorded revenue of 1.
25 billion yuan, a year-on-year increase of 27.
4 times
.
Orient Bio achieved a net profit of 2.
742 billion yuan in the first half of the year, a year-on-year decrease of 19.
23%
.
Regarding the reasons for the changes in performance, Oriental Bio explained that in the first half of the year, the sales volume of the company's products increased significantly year-on-year, but the price of products was adjusted significantly, resulting in "increasing revenue but not profit
.
"
Wantai Bio achieved a net profit of about 2.
693 billion yuan in the first half of the year, a year-on-year increase of 273.
24%
.
Regarding the growth of performance, Wantai Bio said that during the reporting period, the company's bivalent HPV vaccine continued to maintain a boom in production and sales, and revenue and profit achieved rapid growth
.
At the same time, due to the impact of the epidemic at home and abroad, the company's revenue and profits from related raw materials and testing reagents have achieved rapid growth
.
Baiyunshan achieved a net profit of 2.
59 billion yuan in the first half of the year, a year-on-year increase of 3.
5%
.
The company said that during the reporting period, Great Southern Medicine seized the opportunity to expand the market and actively promoted the adjustment of the marketing model; vigorously promoted the concept of "fashionable traditional Chinese medicine", focused on resources to create varieties in various fields, tapped the potential of second-tier echelon products, etc.
The number of key varieties has grown rapidly; the brand influence of Baiyun Mountain has been continuously enhanced, the Group's revitalization project has been actively promoted, and the popularity and recognition of the brand and products have been continuously improved
.
In addition, Xinhecheng achieved a net profit of about 2.
214 billion yuan in the first half of this year; Changchun High-tech achieved a net profit of 2.
12 billion yuan; Hengrui Medicine achieved a net profit of about 2.
119 billion yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is worth mentioning that 14 pharmaceutical companies including Jiu’an Medical, Mindray Medical, and WuXi AppTec achieved a net profit of more than 2 billion yuan
.
According to the semi-annual performance report released by Jiu'an Medical, in the first half of this year, the company achieved a net profit attributable to the parent of 15.
244 billion yuan, a year-on-year increase of 27728.
49%; the deducted non-net profit was 15.
286 billion yuan, a year-on-year increase of 319,397.
92%
.
Jiu'an Medical said that the company's performance growth was mainly driven by the substantial increase in the sales of iHealth series products, but the demand for products is directly related to the development of the epidemic in the United States and local epidemic prevention policies
.
The uncertainty of the epidemic is strong, so the demand, sales and company performance of the company's products are not particularly stable
.
In the first half of this year, Mindray Medical achieved a net profit of 5.
288 billion yuan attributable to its parent, a year-on-year increase of 21.
71%; and a non-net profit of 5.
247 billion yuan, a year-on-year increase of 21.
76%
.
Regarding the substantial growth in performance, Mindray Medical stated that first, the company's main business continued to show a good development trend during the reporting period, and the product competitiveness continued to strengthen, and the mid-to-high-end sales of the product structure increased steadily; second, the company focused on the direction of strategic development planning, steadily Promoting various tasks in an orderly manner, actively exerting operational advantages in R&D, technology, procurement, manufacturing, quality, products, markets, channels, services, etc.
, integrating business resources, and continuously increasing market development efforts, both product sales and income have been achieved.
Healthy and stable growth; at the same time, the company's management has strengthened the continuous improvement of operating efficiency, so the growth of net profit is higher than that of operating income, and the net profit margin has improved significantly
.
In the first half of the year, WuXi AppTec realized a net profit of 4.
636 billion yuan attributable to shareholders of listed companies, a year-on-year increase of 73.
29%; deducted non-net profit of 3.
850 billion yuan, an increase of 81% year-on-year
.
WuXi AppTec attributed its performance growth in the first half of this year to the company's continued strengthening of its unique integrated CRDMO (Contract Research, Development, and Manufacturing) and CTDMO (Contract Testing, R&D, and Manufacturing) business models, while actively cooperating with the implementation of epidemic prevention in Shanghai.
Control measures to give full play to the advantages of global layout, multi-location operation and coverage of the whole industry chain
.
Zhifei Biological realized a net profit of 3.
729 billion yuan attributable to owners of the parent company
.
It is reported that in the first half of the year, Zhifei Biotechnology continued to focus on the vaccine industry, optimize resource allocation, fully ensure the research and development progress, production and supply of each product under development, continue to increase research and development investment, innovate research and development technology, and continue to make efforts closely around the annual business development goals.
, implement the "technology + market" two-wheel-driven development model, and achieve continuous growth in sales revenue
.
Daan Gene achieved a net profit of 3.
595 billion yuan in the first half of the year, a year-on-year increase of 124.
96%
.
The company stated that the substantial growth in sales of nucleic acid detection kits is the main driving force behind the substantial growth in revenue and net profit in the first half of 2022
.
In the first half of the year, Anxu Bio achieved a net profit of 2.
878 billion yuan attributable to its parent, a year-on-year increase of 1323.
7%
.
Regarding the sharp increase in net profit, the company stated that it was mainly due to the substantial increase in the company's operating income and the simultaneous increase in net profit during the reporting period
.
It is reported that in the first half of the year, the company achieved revenue of 5.
93 billion yuan, a year-on-year increase of 1100.
35%
.
In the first half of the year, Mingde Bio achieved a net profit of 2.
76 billion yuan, a year-on-year increase of 376.
29%
.
It is reported that in the first half of the year, the company's immunodiagnostic product revenue increased significantly year-on-year
.
The company's antigen detection reagents recorded revenue of 1.
25 billion yuan, a year-on-year increase of 27.
4 times
.
Orient Bio achieved a net profit of 2.
742 billion yuan in the first half of the year, a year-on-year decrease of 19.
23%
.
Regarding the reasons for the changes in performance, Oriental Bio explained that in the first half of the year, the sales volume of the company's products increased significantly year-on-year, but the price of products was adjusted significantly, resulting in "increasing revenue but not profit
.
"
Wantai Bio achieved a net profit of about 2.
693 billion yuan in the first half of the year, a year-on-year increase of 273.
24%
.
Regarding the growth of performance, Wantai Bio said that during the reporting period, the company's bivalent HPV vaccine continued to maintain a boom in production and sales, and revenue and profit achieved rapid growth
.
At the same time, due to the impact of the epidemic at home and abroad, the company's revenue and profits from related raw materials and testing reagents have achieved rapid growth
.
Baiyunshan achieved a net profit of 2.
59 billion yuan in the first half of the year, a year-on-year increase of 3.
5%
.
The company said that during the reporting period, Great Southern Medicine seized the opportunity to expand the market and actively promoted the adjustment of the marketing model; vigorously promoted the concept of "fashionable traditional Chinese medicine", focused on resources to create varieties in various fields, tapped the potential of second-tier echelon products, etc.
The number of key varieties has grown rapidly; the brand influence of Baiyun Mountain has been continuously enhanced, the Group's revitalization project has been actively promoted, and the popularity and recognition of the brand and products have been continuously improved
.
In addition, Xinhecheng achieved a net profit of about 2.
214 billion yuan in the first half of this year; Changchun High-tech achieved a net profit of 2.
12 billion yuan; Hengrui Medicine achieved a net profit of about 2.
119 billion yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
